Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05549505 · ClinicalTrials.gov registry record · Phase 2
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
A Phase 2 study, sponsored by Arvinas.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT05549505 is a Phase 2 study that has completed, run by Arvinas. The registered enrollment target is 152 participants.
The verdict
NCT05549505, a Phase 2 study, has completed, sponsored by Arvinas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
Interventions
- DRUG Anastrozole
- DRUG ARV-471
- PROCEDURE Surgical resection of breast tumor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2023-02-15 |
| Est. Completion | 2024-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05549505
The ClinicalTrials.gov registry entry for NCT05549505 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arvinas, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Anastrozole is the first listed.
NCT05549505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05549505 about?
NCT05549505 is a clinical study titled "A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery". This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with estrogen receptor positive/ human epidermal growth factor receptor 2 (ER+/HER2)- localized breast cancer.
What is the current status of trial NCT05549505?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2023-02-15. Estimated completion is 2024-07-25.
What interventions are being tested in trial NCT05549505?
The interventions under investigation include: Anastrozole (DRUG), ARV-471 (DRUG), Surgical resection of breast tumor (PROCEDURE).
Who is sponsoring clinical trial NCT05549505?
This trial is sponsored by Arvinas, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.